Brielle Cornelius
Nurse Practitioner · Olean, NYNPI 1285360313
Payments from drug & device makers
Across 200 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$865
- AstraZeneca$645
- Bayer$527
- Amgen$261
- Calliditas Therapeutics US Inc.$161
- Lilly USA, LLC$146
- plus $992 from 14 others
What the payments were for
- Food & beverage$3,27291%
- Education$3259%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 73 | $865 |
| AstraZeneca | 30 | $645 |
| Bayer | 33 | $527 |
| Amgen | 11 | $261 |
| Calliditas Therapeutics US Inc. | 6 | $161 |
| Lilly USA, LLC | 6 | $146 |
| Boehringer Ingelheim | 7 | $135 |
| Otsuka America Pharmaceutical, Inc. | 5 | $123 |
| Ardelyx, Inc. | 5 | $121 |
| Novartis | 4 | $108 |
| Esperion Therapeutics, Inc. | 1 | $82 |
| Novo Nordisk | 3 | $82 |
| ANI Pharmaceuticals, Inc. | 4 | $73 |
| Kyowa Kirin, Inc. | 2 | $49 |
| OPKO Pharmaceuticals, LLC | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Fresenius USA Marketing, Inc. | 2 | $39 |
| Vifor Pharma, Inc. | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
How this compares
$3,597 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 31 | $87,221 |
| JardianceEmpagliflozin | 108 | $65,829 |
| MounjaroTirzepatide | 43 | $46,272 |
| FarxigaDapagliflozin Propanediol | 54 | $45,250 |
| KerendiaFinerenone | 57 | $37,437 |
| Calcium Acetate | 70 | $10,143 |
| Cinacalcet Hcl | 23 | $6,721 |
| DapagliflozinDapagliflozin Propanediol | 12 | $4,971 |
| Sevelamer Carbonate | 26 | $4,247 |
| Calcitriol | 85 | $953 |
| Amlodipine Besylate | 109 | $841 |
| Losartan Potassium | 54 | $515 |
| Bumetanide | 28 | $515 |
| Carvedilol | 54 | $407 |
| Hydrochlorothiazide | 27 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $135 | $65,829108 claims |
| Lilly USA, LLCMounjaro | $146 | $46,27243 claims |
| AstraZenecaFarxiga | $645 | $45,25054 claims |
| BayerKerendia | $527 | $37,43757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Olean
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.